Imugene宣布以每股0.33澳元价格完成2250万美元配售 同步启动1500万澳元购股计划

华尔街洞察
16 Jul

澳大利亚生物制药企业Imugene(ASX:IMU)今日披露重大融资进展。该公司已成功获得总额2250万美元(约合3300万澳元)的机构配售确定承诺,配售价格定为每股0.33澳元。此次配售获得市场积极响应,彰显投资者对公司发展前景的信心。

在完成配售的同时,Imugene宣布启动上限为1500万澳元的购股计划。该计划将面向现有合格股东,以与机构配售相同的每股0.33澳元价格进行募资。两项融资计划合计可为公司注入最高约4800万澳元的营运资金。

此次融资将主要用于推进公司核心免疫肿瘤疗法的临床研发。作为专注于癌症免疫治疗领域的创新企业,Imugene管线包含多款处于临床阶段的候选药物,此次资金到位将加速其关键项目的试验进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10